Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Non-Hodgkin-Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00179673
What this trial is testing

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Celgene 43
Testing effectiveness (Phase 2)Study completedNCT04605666
What this trial is testing

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Nanfang Hospital, Southern Medical University 77
Testing effectiveness (Phase 2)Study completedNCT03493451
What this trial is testing

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Who this might be right for
Peripheral T Cell LymphomaPTCLExtranodal NK/T-cell Lymphoma+16 more
BeiGene 77
Early research (Phase 1)UnknownNCT04008251
What this trial is testing

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell Lymphoma
Wuhan Sian Medical Technology Co., Ltd 10
Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Early research (Phase 1)Active Not RecruitingNCT03952078
What this trial is testing

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Who this might be right for
T-cell Lymphoma
Corvus Pharmaceuticals, Inc. 151
Early research (Phase 1)Not Yet RecruitingNCT07616089
What this trial is testing

Phase I Study of FXS0683 in the Treatment of Blood Tumors

Who this might be right for
B-Cell LymphomaAcute Myeloid LeukemiaMyelodysplastic Syndromes+1 more
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 228
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Early research (Phase 1)WithdrawnNCT02657447
What this trial is testing

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Who this might be right for
Non-Hodgkin Lymphoma
Nordic Nanovector
Testing effectiveness (Phase 2)Ended earlyNCT06088654
What this trial is testing

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
Innate Pharma 23
Testing effectiveness (Phase 2)Ended earlyNCT01135329
What this trial is testing

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Who this might be right for
LymphomaLeukemiaMyelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 15
Early research (Phase 1)WithdrawnNCT01789723
What this trial is testing

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Who this might be right for
Non Hodgkin's Lymphoma
Acrotech Biopharma Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07508605
What this trial is testing

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital 20
Not applicableStudy completedNCT07103486
What this trial is testing

Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals 264
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Early research (Phase 1)WithdrawnNCT02487459
What this trial is testing

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Who this might be right for
Hematologic Malignancies
Bellicum Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00445341
What this trial is testing

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 28
Early research (Phase 1)Study completedNCT02309580
What this trial is testing

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Who this might be right for
T-cell LymphomaRelapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)WithdrawnNCT03880279
What this trial is testing

Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Triumvira Immunologics, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155620
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+42 more
National Cancer Institute (NCI) 1,377
Next Page